Xenon Pharmaceuticals Inc. (XENE)

Market Cap	5.57B +109.3%
Revenue (ttm)	7.50M
Net Income	-345.91M
EPS	-4.36
Shares Out	95.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	655,881
Open	58.45
Previous Close	58.59
Day's Range	57.87 - 59.03
52-Week Range	28.19 - 63.95
Beta	0.75
Analysts	Strong Buy
Price Target	67.17 (+15.02%)
Earnings Date	May 11, 2026

About XENE

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2014
• Employees: 370
• Stock Exchange: NASDAQ
• Ticker Symbol: XENE
• Website: https://www.xenon-pharma.com

Analyst Summary

According to 12 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $67.17, which is an increase of 15.02% from the latest price.

Price Target

$67.17

(15.02% upside)

Analyst Consensus: Strong Buy